Literature DB >> 26499800

Coupling between Nutrient Availability and Thyroid Hormone Activation.

Lattoya J Lartey1, João Pedro Werneck-de-Castro2, InSug O-Sullivan3, Terry G Unterman3, Antonio C Bianco4.   

Abstract

The activity of the thyroid gland is stimulated by food availability via leptin-induced thyrotropin-releasing hormone/thyroid-stimulating hormone expression. Here we show that food availability also stimulates thyroid hormone activation by accelerating the conversion of thyroxine to triiodothyronine via type 2 deiodinase in mouse skeletal muscle and in a cell model transitioning from 0.1 to 10% FBS. The underlying mechanism is transcriptional derepression of DIO2 through the mTORC2 pathway as defined in rictor knockdown cells. In cells kept in 0.1% FBS, there is DIO2 inhibition via FOXO1 binding to the DIO2 promoter. Repression of DIO2 by FOXO1 was confirmed using its specific inhibitor AS1842856 or adenoviral infection of constitutively active FOXO1. ChIP studies indicate that 4 h after 10% FBS-containing medium, FOXO1 binding markedly decreases, and the DIO2 promoter is activated. Studies in the insulin receptor FOXO1 KO mouse indicate that insulin is a key signaling molecule in this process. We conclude that FOXO1 represses DIO2 during fasting and that derepression occurs via nutritional activation of the PI3K-mTORC2-Akt pathway.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  FOXO1; insulin; mTOR complex (mTORC); signal transduction; signaling; thyroid hormone; type 2 deiodinase

Mesh:

Substances:

Year:  2015        PMID: 26499800      PMCID: PMC4683275          DOI: 10.1074/jbc.M115.665505

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  54 in total

Review 1.  Type 2 deiodinase at the crossroads of thyroid hormone action.

Authors:  Rafael Arrojo E Drigo; Antonio C Bianco
Journal:  Int J Biochem Cell Biol       Date:  2011-06-12       Impact factor: 5.085

Review 2.  Minireview: cracking the metabolic code for thyroid hormone signaling.

Authors:  Antonio C Bianco
Journal:  Endocrinology       Date:  2011-06-28       Impact factor: 4.736

3.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1.

Authors:  Katrin Düvel; Jessica L Yecies; Suchithra Menon; Pichai Raman; Alex I Lipovsky; Amanda L Souza; Ellen Triantafellow; Qicheng Ma; Regina Gorski; Stephen Cleaver; Matthew G Vander Heiden; Jeffrey P MacKeigan; Peter M Finan; Clary B Clish; Leon O Murphy; Brendan D Manning
Journal:  Mol Cell       Date:  2010-07-30       Impact factor: 17.970

Review 4.  mTOR complex 2 signaling and functions.

Authors:  Won Jun Oh; Estela Jacinto
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

Review 5.  Mammalian TOR signaling to the AGC kinases.

Authors:  Bing Su; Estela Jacinto
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-10-10       Impact factor: 8.250

Review 6.  mTor signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong?

Authors:  Robert A Frost; Charles H Lang
Journal:  Physiology (Bethesda)       Date:  2011-04

7.  Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice.

Authors:  Takeyuki Nagashima; Nobuharu Shigematsu; Riyo Maruki; Yasuharu Urano; Hirotsugu Tanaka; Akiyoshi Shimaya; Teruhiko Shimokawa; Masayuki Shibasaki
Journal:  Mol Pharmacol       Date:  2010-08-24       Impact factor: 4.436

8.  Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Authors:  Hernan Carol; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Catherine Billups; Malcolm A Smith; Peter J Houghton; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2010-08-25       Impact factor: 3.167

9.  The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration.

Authors:  Monica Dentice; Alessandro Marsili; Raffaele Ambrosio; Ombretta Guardiola; Annarita Sibilio; Ji-Hye Paik; Gabriella Minchiotti; Ronald A DePinho; Gianfranco Fenzi; P Reed Larsen; Domenico Salvatore
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

10.  Absence of thyroid hormone activation during development underlies a permanent defect in adaptive thermogenesis.

Authors:  Jessica A Hall; Scott Ribich; Marcelo A Christoffolete; Gordana Simovic; Mayrin Correa-Medina; Mary Elizabeth Patti; Antonio C Bianco
Journal:  Endocrinology       Date:  2010-07-21       Impact factor: 4.736

View more
  20 in total

Review 1.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

2.  The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia.

Authors:  Gustavo W Fernandes; Barbara M L C Bocco; Tatiana L Fonseca; Elizabeth A McAninch; Sungro Jo; Lattoya J Lartey; InSug O-Sullivan; Terry G Unterman; Nailliw Z Preite; Robin M Voigt; Christopher B Forsyth; Ali Keshavarzian; Richárd Sinkó; Allison B Goldfine; Mary E Patti; Miriam O Ribeiro; Balázs Gereben; Antonio C Bianco
Journal:  Cell Rep       Date:  2018-01-09       Impact factor: 9.423

3.  Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors:  Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal:  Expert Opin Ther Targets       Date:  2020-01-15       Impact factor: 6.902

4.  Thyroid Function Variation in the Normal Range, Energy Expenditure, and Body Composition in L-T4-Treated Subjects.

Authors:  Mary H Samuels; Irina Kolobova; Megan Antosik; Meike Niederhausen; Jonathan Q Purnell; Kathryn G Schuff
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

5.  Early Developmental Disruption of Type 2 Deiodinase Pathway in Mouse Skeletal Muscle Does Not Impair Muscle Function.

Authors:  Daniele L Ignacio; Diego H S Silvestre; Elena Anne-Palmer; Barbara M L C Bocco; Tatiana L Fonseca; Miriam O Ribeiro; Balázs Gereben; Antonio C Bianco; Joao P Werneck-de-Castro
Journal:  Thyroid       Date:  2017-02-10       Impact factor: 6.568

6.  Effects of Altering Levothyroxine Dose on Energy Expenditure and Body Composition in Subjects Treated With LT4.

Authors:  Mary H Samuels; Irina Kolobova; Meike Niederhausen; Jonathan Q Purnell; Kathryn G Schuff
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

7.  Is a Normal TSH Synonymous With "Euthyroidism" in Levothyroxine Monotherapy?

Authors:  Sarah J Peterson; Elizabeth A McAninch; Antonio C Bianco
Journal:  J Clin Endocrinol Metab       Date:  2016-10-04       Impact factor: 5.958

8.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Anne R Cappola; Francesco S Celi; Eric Fliers; Heike Heuer; Elizabeth A McAninch; Lars C Moeller; Birte Nygaard; Anna M Sawka; Torquil Watt; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2021-02-16

Review 9.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Anne R Cappola; Francesco S Celi; Eric Fliers; Heike Heuer; Elizabeth A McAninch; Lars C Moeller; Birte Nygaard; Anna M Sawka; Torquil Watt; Colin M Dayan
Journal:  Thyroid       Date:  2021-02       Impact factor: 6.568

Review 10.  The Interplay Between Thyroid Dysfunction and Kidney Disease.

Authors:  Yoko Narasaki; Peter Sohn; Connie M Rhee
Journal:  Semin Nephrol       Date:  2021-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.